David Kirn compensation by year
4D Molecular Therapeutics Summary Compensation Table · all 7 fiscal years held| Component | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Salary | $430,000 | $451,189 | $570,000 | $585,720 | $596,640 | $662,780 | $667,252 |
| Bonus | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Stock awards | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Option awards | $0 | $0 | $4,389,825 | $2,367,000 | $9,278,715 | $0 | $822,750 |
| Non-equity incentive | $111,800 | $237,344 | $228,000 | $321,750 | $394,953 | $292,662 | $560,597 |
| Pension and deferred compensation | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| All other | $12,500 | $13,000 | $13,000 | $13,500 | $16,500 | $53,561 | $744 |
| Total | $554,300 | $701,533 | $5,200,825 | $3,287,970 | $10,286,808 | $1,009,004 | $2,051,343 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: 4D Molecular Therapeutics, Inc. DEF 14A filed April 28, 2026, accession 0001140361-26-017427, and prior-year filings. Open the filing on EDGAR.
How this page was built: the 4D Molecular Therapeutics, Inc. filed document, accession 0001140361-26-017427. Every figure is read from that document and cited to the page and table it appears in. Filed April 28, 2026.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| Option | 6,250 | — | $15.78 |
| Option | 64,750 | — | $20.24 |
| Option | 295,000 | — | $14.42 |
| Option | 217,344 | — | $4.14 |
Per the Outstanding Equity Awards at Fiscal Year-End table in 4D Molecular Therapeutics, Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
14 Form 4 lines since the FY2025 proxy (filed April 28, 2026)current to 2026-11-07 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-10-05 | Sale | 10b5-1 | 58,061 | $12.92 | 709,425 |
| 2026-10-05 | Sale | 10b5-1 | 272 | $13.61 | 709,153 |
| 2026-09-14 | Sale | 10b5-1 | 58,333 | $13.90 | 767,486 |
| 2026-08-19 | Sale | 10b5-1 | 43,149 | $15.36 | 851,746 |
| 2026-08-19 | Exercise or conversion derivative | 10b5-1 | 50,000 | $0.00 | 217,500 |
| 2026-08-19 | Exercise or conversion | 10b5-1 | 50,000 | $4.14 | 894,895 |
| 2026-08-19 | Sale | 10b5-1 | 25,927 | $16.42 | 825,819 |
| 2026-08-04 | Sale | 10b5-1 | 26,842 | $10.23 | 844,895 |
The 8 most recent of 14 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
4D Molecular Therapeutics’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Kristian Humer | Chief Financial Officer | $3,990,903 |
| David Kirn · this page | President and Chief Executive Officer | $2,051,343 |
| Fariborz Kamal | Former Chief Operating Officer & President | $1,441,573 |
Board service
4D Molecular Therapeutics board · FY2021–FY2025How this board is paid
Company policy: 4D Molecular Therapeutics pays directors a $40,000 cash retainer and $70,000 in Options. As stated in 4D Molecular Therapeutics's FY2025 proxy.
The full 4D Molecular Therapeutics compensation record
free company briefThis page is one person within 4D Molecular Therapeutics's record. The company brief lists every named executive, each linking to their own page.
Compensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order 4D Molecular Therapeutics's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are 4D Molecular Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Order FDMT
Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.